Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer

奥西默替尼 医学 肺癌 肿瘤科 耐受性 化疗 内科学 埃罗替尼 临床试验 癌症 表皮生长因子受体 不利影响
作者
Alessia Spagnuolo,Cesare Gridelli
出处
期刊:Expert Opinion on Pharmacotherapy [Taylor & Francis]
卷期号:: 1-11
标识
DOI:10.1080/14656566.2025.2464903
摘要

Worldwide, 15-40% of advanced-stage non-small cell lung cancers (NSCLCs) have an activating EGFR mutation, treatable with tyrosine-kinase inhibitors (TKIs) such as osimertinib, recommended as front-line therapy. Despite the efficacy of first-line osimertinib, most patients will experience disease progression. Therefore, combining it with chemotherapy has become an area of interest. Osimertinib is a third-generation EGFR-TKI that has extended survival in NSCLC patients with EGFR mutation. However, resistance eventually leads to treatment failure. This has driven the advancement of strategies to overcome resistance to osimertinib. In this setting, the FLAURA2 trial yielded positive results by combining osimertinib with chemotherapy. Additionally, a range of other approaches, including the use of bispecific antibodies and antibody-drug conjugates alongside third-generation EGFR-TKIs or chemotherapy, support the development of novel therapeutic combinations, some of which have already been approved for EGFR-mutated advanced NSCLC. Next to osimertinib monotherapy, expanded upfront treatment options for patients with EGFR-mutated advanced NSCLC require patient selection considering disease extent, toxicity and tolerability, dosing schedule and what the patient can expect through shared decision-making. Further studies are needed to identify the patients who will benefit the most from combination therapies and to sequence the new drugs into the treatment algorithm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
南风发布了新的文献求助30
1秒前
1秒前
2秒前
Orange应助大佬虎采纳,获得30
2秒前
自觉的傲薇应助行走的鱼采纳,获得20
3秒前
扎心发布了新的文献求助10
3秒前
9527完成签到,获得积分10
3秒前
wildeager完成签到,获得积分10
3秒前
3秒前
皮雁子发布了新的文献求助10
3秒前
脑洞疼应助ddd采纳,获得10
3秒前
研友_pnxAJZ发布了新的文献求助10
4秒前
天天快乐应助白筠233采纳,获得10
4秒前
4秒前
4秒前
今后应助包子采纳,获得10
4秒前
5秒前
Ava应助害羞洋葱采纳,获得10
5秒前
6秒前
ccc完成签到 ,获得积分10
6秒前
1233330完成签到,获得积分10
6秒前
学阀发布了新的文献求助10
6秒前
7秒前
七七完成签到 ,获得积分10
7秒前
7秒前
shuangshine7完成签到,获得积分10
8秒前
8秒前
lin应助AJ采纳,获得10
8秒前
8秒前
64658应助ayuelei采纳,获得10
9秒前
暗栀发布了新的文献求助10
9秒前
00完成签到 ,获得积分10
9秒前
9秒前
9秒前
哇哦发布了新的文献求助20
10秒前
10秒前
minino完成签到 ,获得积分10
10秒前
11秒前
叶子完成签到,获得积分10
12秒前
jim_hacker发布了新的文献求助10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969335
求助须知:如何正确求助?哪些是违规求助? 3514162
关于积分的说明 11172430
捐赠科研通 3249456
什么是DOI,文献DOI怎么找? 1794853
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804809